# Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

> **NCT07151560** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Renmin Hospital of Wuhan University** · enrollment: 60 (estimated)

## Conditions studied

- Urology

## Interventions

- **DRUG:** 6 cycle RC48 and JS001
- **DRUG:** 12 cycle RC48 and JS001

## Key facts

- **NCT ID:** NCT07151560
- **Lead sponsor:** Renmin Hospital of Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2027-08-30
- **Final completion:** 2030-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151560, "Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07151560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*